Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 601–700 of 1,000
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
“In terms of administration, semaglutide and tirzepatide are once-a-week formulations, whereas liraglutide is a daily formulation [12, 14].”
Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability
Harms, M., Haase, A., Rodríguez, A., Löffler, J., Almeida‐Hernández, Y., Ruiz‐Blanco, Y. B., Albers, D., Gilg, A., von Bank, F., Zech, F., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.049 · Cited by 9
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Alfawaz, S. A., Burzangi, A. S., & Esmat, A. (2024) · Cureus · doi:10.7759/cureus.67080 · Cited by 16
“Semaglutide has an extended half-life of approximately one week, which makes it optimal for once-weekly injections [127,128].”
BackgroundPantea, I., Repanovici, A., & Andreescu, O. (2024) · Medicina · doi:10.3390/medicina60111761 · Cited by 10
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
“Structural differences include amino acid substitution at position 8 (alanine to α -aminoisobutyric acid) and position 34 (lysine to arginine), and acylation of the lysine in position 26 with a spacer and C-18 fatty acid chain [14].”
Yang, S., Clemett, C. A., Brimble, M. A., O’Carroll, S. J., & Harris, P. W. R. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00172d · Cited by 10
Choi, J., Wahlgren, M., Ek, V., Elofsson, U. M., Fransson, J., Nilsson, L., Terry, A. E., & Söderberg, C. A. G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242605 · Cited by 9
“For example, insulin-like peptides have shown considerably increase in half-life when lipidated [9].”
Baek, C. H., Kim, H., Moon, S. Y., & Yang, W. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120331 · Cited by 10
Efficient synthesis of Aib8‐Arg34‐GLP‐1 (7–37) by liquid‐phase fragment condensation
Zhang, J., Dong, Y., He, Y., Han, J., Hu, H., & Feng, J. (2022) · Journal of Peptide Science · doi:10.1002/psc.3407 · Cited by 9
“These two improvements have significantly increased the in vivo half-life of semaglutide, which is administered once a week [8].”
Backgroundα/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo
Shi, Y., Lee, C., Sang, P., Amso, Z., Huang, D., Zhong, W., Gu, M., Wei, L., Nguyen-Tran, V. T. B., Zhang, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.014 · Cited by 9
Search for lipidized PrRP analogs with strong anorexigenic effect: In vitro and in vivo studies
Strnadová, V., Karnošová, A., Blechová, M., Neprašová, B., Holá, L., Němcová, A., Myšková, A., Sýkora, D., Železná, B., Kuneš, J., et al. (2023) · Neuropeptides · doi:10.1016/j.npep.2022.102319 · Cited by 10
Esposito, S., Krick, A., Pasquier, O., Bonche, F., Ingenito, R., Magotti, P., Bianchi, E., Monteagudo, E. S., Gallo, M. L., Cicero, D. O., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115256 · Cited by 10
Zhu, J., Wang, H., Yan, C., Li, B., & Chen, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19873 · Cited by 9
“Semaglutide (Sem), as a long-acting analog with high homology with GLP-1, has strong affinity with GLP-1 receptor (GLP-1R) in vitro [11].”
BackgroundShi, F., Li, H., Cui, M., Zhang, Z.-L., Gu, Z., & Liu, X.-Y. (2018) · Medicine · doi:10.1097/md.0000000000010420 · Cited by 13
Pflimlin, E., Zhou, Z., Amso, Z., Fu, Q., Lee, C., Muppidi, A., Joseph, S. B., Nguyen-Tran, V. T. B., & Shen, W. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01862 · Cited by 9
“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
DiMarchi, R. D. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.10.004 · Cited by 8
“These include an identical substitution at the second position to prevent DPP4 proteolysis and lipidation as observed in semaglutide but with a slightly longer fatty acid [3].”
BackgroundShan, X., Wang, Y., Xiao, X., Gao, Y., & Sun, X. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.09.013 · Cited by 8
Pawlas, J., & Lindgren, A. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c00423 · Cited by 8
Lu, Y., Jiang, X. Y., Yang, B., Ding, M., Shen, Y., Jin, J., Yu, J., Lu, W. P., Chen, Y., & Zhu, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03096 · Cited by 8
Plasma Protein Binding as an Optimizable Parameter for In Vivo Efficacy
Zhao, H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00964 · Cited by 8
Molecular Design of Unimolecular Tetra-Receptor Agonists
Dinsmore, T. C., Cortigiano, J. E., Xiang, S., Spenciner, M. V., Dobbins, A. R., Zhao, R. R., Waldman, B. M., Beinborn, M., & Kumar, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04095 · Cited by 12
Yeşilyurt, Z. E., Matthes, J., Hintermann, E., Castañeda, T. R., Elvert, R., Beltran‐Ornelas, J. H., Silva‐Velasco, D. L., Xia, N., Kannt, A., Christen, U., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.923555 · Cited by 9
Zhang, C., Gao, G., Li, Y., Ying, J., Li, J., & Hu, S. (2023) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-131015 · Cited by 8
“By employing these strategies, semaglutide, and dulaglutide have achieved extended half-lives of up to 7 and 5 days in humans, respectively (22, 23).”
BackgroundMethodInfluentialNapier, P., Bakas, N. A., Bhat, A., & Noncovich, A. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02115 · Cited by 8
Discovery of a long-acting glucagon-like peptide-1 analog with enhanced aggregation propensity
Takeuchi, M., Okamoto, M., Okamoto, R., Kinoshita, H., Yamaguchi, Y., & Watanabe, N. (2018) · Peptides · doi:10.1016/j.peptides.2018.01.014 · Cited by 8
“Moreover, the choice of the spacer between the backbone peptide and the fatty acid is also detrimental [4,5].”
BackgroundTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 10
Adapting the Glaser Reaction for Bioconjugation: Robust Access to Structurally Simple, Rigid Linkers
Silvestri, A. P., Cistrone, P. A., & Dawson, P. E. (2017) · Angewandte Chemie · doi:10.1002/ange.201705065 · Cited by 8
Discovery of Once-Weekly, Peptide-Based Selective Glp-1 and Cholecystokinin 2 Receptors Co-Agonists
Zhou, F. L., Song, P. K., Tang, X., Yang, Q., Zhou, S., Xu, R., Fang, T., Jia, Z., & Han, J. D. J. (2022) · Peptides · doi:10.1016/j.peptides.2022.170811 · Cited by 9
Clinical Practice Guideline for the Management of Overweight and Obesity in Adults in Saudi Arabia
Alshaikh, A., Al-Jedai, A. H., Alfadda, A. A., Al-Robayan, A. A., Bawahab, A., Abo’ouf, S., Sultan, A., Alhozali, A. M., Bawazeer, M. A., Sheshah, E., et al. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.1312045 · Cited by 9
de Lucas, M. D. G., Caballero, I., Fernández‐García, J. C., Domínguez-Rodríguez, M., Moreno-Moreno, P., Jiménez-Millán, A., Botana-López, M. A., Avilés, B., Merino-Torres, J. F., Soto, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240279 · Cited by 10
Designing Orally Bioavailable Peptide and Peptoid Macrocycles
Price, D. A., Mathiowetz, A. M., & Liras, S. I. (2017) · Wiley eBooks · doi:10.1002/9781119092599.ch3 · Cited by 8
Design of stapled oxyntomodulin analogs containing functionalized biphenyl cross-linkers
Tian, Y., Zou, H., An, P., Zhou, Z., Shen, W., & Lin, Q. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.11.060 · Cited by 9
Cary, B. P., Hager, M. V., & Gellman, S. H. (2019) · ChemBioChem · doi:10.1002/cbic.201900300 · Cited by 9
GLP-1 analogues in clinical management of obesity
Agius, R., Matta-Coelho, C., & McGowan, B. M. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100360 · Cited by 9
Wang, P., Hill, T. A., Mitchell, J. M., Fitzsimmons, R. L., Xu, W., Loh, Z., Suen, J. Y., Lim, J., Iyer, A., & Fairlie, D. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00653 · Cited by 8
A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
Selvarajan, R., & Subramanian, R. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s385196 · Cited by 8
“They can also be classed according to their duration, apart from structural categorization (short-acting and long-acting GLP-1 RAs).(33) Exenatide (administrated twice daily), liraglutide and lixisenatide (given once every day), and once weekly exenatide-extended-release, albiglutide and dulaglutide are now authorized…”
BackgroundSqualene-PEG-Exendin as High-Affinity Constructs for Pancreatic Beta-Cells
Babič, A., Vinet, L., Chellakudam, V., Janikowska, K., Allémann, É., & Lange, N. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00186 · Cited by 9
Sun, L., Han, J. D. J., Chen, X., Han, Y., Wu, L., & Xia, E. (2019) · RSC Advances · doi:10.1039/c9ra00833k · Cited by 9
Han, J. D. J., Fu, J., Yang, Q., Zhou, F. L., Chen, X., Li, C., & Yin, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112389 · Cited by 9
Damholt, B. B., Dombernowsky, S. L., Bendtsen, M. D., Bisgaard, C., & Rasmussen, M. H. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-00990-7 · Cited by 8
Semaglutide for nonalcoholic steatohepatitis: closer to a solution?
Liava, C., & Sinakos, E. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-231 · Cited by 8
Inia, J. A., van Nieuwkoop, A., Jukema, J. W., Rolin, B., Staarup, E. M., Mogensen, C., Princen, H. M. G., & van den Hoek, A. M. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100753 · Cited by 7
“To enhance intestinal absorption, to improve the stability of the peptide and to increase albumin affinity, Novo Nordisk ’ s fatty acid acylation technology was used to obtain a long half-life and a long duration of action of the peptide (14).”
Deng, B., Su, P. J., Lu, C. Y., Zhang, J., Zhang, X., Yu, T., Bao, G., Yan, T., Yin, Y. H., Shen, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00133 · Cited by 7
Zhang, C., Dong, G., Wu, X. Q., Chen, J., Wang, Y., Gong, L., Yang, X., Shi, Y., Gu, Z., Gao, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00147 · Cited by 7
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“The next iteration, semaglutide, possessed a 7-day half-life, allowing for once weekly administration [35,37].”
Obesity and cancer: Relevance of DNA damage response
Deshmukh, B., Ajay, A. K., & Bhat, M. K. (2026) · Translational Oncology · doi:10.1016/j.tranon.2025.102657 · Cited by 9
“Semaglutide has enhanced efficacy and pharmacokinetic properties, therefore is effective at lower dosage [93 – 95].”
Niazi, S. K. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1776167 · Cited by 8
“The molecular basis of these modifications and their contribution to pharmacokinetic performance have been described in detail during the discovery and optimization of semaglutide (Lau et al., 2015) (Figure 3).”
Semaglutide ameliorates neuroinflammation and cognitive impairment in APP/PS1 mice
Yuan, Y., ZHANG, J., Zhang, Z., Zhai, Y., Cheng, X. J., Xue, L., Zhao, F., Cao, L., & Wang, H. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05568-0 · Cited by 8
“Semaglutide, a long-acting GLP-1 analogue administered once weekly, is widely used for the treatment of obesity and type 2 diabetes [19, 43 ] and has also shown benefits on cardiovascular and cere - brovascular outcomes in metabolic diseases [38, 45, 46].”
Šantić, R., Martinovic, L., Pavlović, N., Rušić, D., Kumrić, M., Martinović, D., Kurir, T. T., & Božić, J. (2026) · Metabolites · doi:10.3390/metabo16060364 · Cited by 11
“These shared pathways should not be interpreted as evidence that liraglutide, semaglu-tide, and tirzepatide are pharmacologically interchangeable [12–15 ,60, 61].”
Hu, W., Sun, Y., Li, T., Williamson, M., Hu, X., & Wang, M. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100009 · Cited by 8
Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist
Lear, S., Seo, H., Lee, C., Lei, L., Amso, Z., Huang, D., Zou, H., Zhou, Z., Nguyen-Tran, V. T. B., & Shen, W. (2020) · Molecules · doi:10.3390/molecules25112508 · Cited by 8
“Lipidation is an established approach for half-life extension of therapeutic peptides, and has found prominence in the metabolic disease space, where many lipidated peptides and proteins such as GLP-1R agonists (semaglutide [8], liraglutide [9]) and insulin analogs (insulin detemir [10] and degludec [11]) have been ap…”
BackgroundGaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“There are currently three available incretin-based medications for the treatment of obesity, liraglutide and semaglutide [9], which are glucagon-like peptide-1 (GLP-1) receptor agonists and tirzepatide which is a dual GLP-1 and a glucose-dependent insulinotropic peptide receptor agonist (GIP)…”
Conformational modulation and polymerization-induced folding of proteomimetic peptide brush polymers
Oktawiec, J., Ebrahim, O. M., Chen, Y., Su, K., Sharpe, C., Rosenmann, N. D., Barbut, C., Weigand, S. L., Thompson, M. P., Byrnes, J., et al. (2024) · Chemical Science · doi:10.1039/d4sc03420a · Cited by 7
Wang, R., Chen, K., Liu, S., Ren, R., Hou, H., Zeng, Q., Zhang, Y., & Liu, Y. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117961 · Cited by 10
Hierarchical Reaction Logic Enables Computational Design of Complex Peptide Syntheses
Molga, K., Beker, W., Roszak, R., Czerwiński, A. A., & Grzybowski, B. A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17057 · Cited by 7
Tordrup, E. K., Gadgaard, S., Windeløv, J. A., Holst, J. J., Gasbjerg, L. S., Hartmann, B., & ROSENKILDE, M. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116893 · Cited by 7
Alturki, M. S., Alkhodier, R. A., Gomaa, M. S., Hussein, D. A., Tawfeeq, N., Khzem, A. H. A., Pottoo, F. H., Albugami, S. A., Aldawsari, M. F., & Rants’o, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136131 · Cited by 7
“Among these, liraglutide, semaglutide, and dulaglutide stand out as some of the most recognized agents [7–9].”
Huang, C., Wille, C. B., He, H., Reddy, V., Nargund, R. P., Lin, S., & Palani, A. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.02.031 · Cited by 7
Hu, S., Wang, S., Qi, C., Gu, S., Shi, C., Mao, L., & Fan, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831364 · Cited by 7
Investigating the Expression and Function of the Glucose Transporter GLUT6 in Obesity
Chen, S.-Y., Olzomer, E. M., Beretta, M., Cantley, J., Nunemaker, C. S., Hoehn, K. L., & Byrne, F. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179798 · Cited by 9
“The ob/ob and db/db models have been important in demonstrating the efficacy of several pharmacotherapies, including exendin-4, liraglutide, and semaglutide, which have since been approved for clinical use, as well as the nowdiscontinued sibutramine [7,8].”
BackgroundRational design of highly stabilized and selective adrenomedullin analogs
Jülke, E., Fischer, J., Els‐Heindl, S., Bierer, D. E., Flamme, I., Köbberling, J., Riedl, B., & Beck‐Sickinger, A. G. (2023) · Journal of Peptide Science · doi:10.1002/psc.3530 · Cited by 7
“31 Therefore, we prepared an ADM 14 – 52 analog with K 14 (Odd) substitution (analog 11 ).”
MethodDesign of a novel long-acting dual GLP-1/GIP receptor agonist
Dong, Y., Zhang, J., Xu, H., Shen, H., Lu, Q., Feng, J., & Cai, Z. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117630 · Cited by 7
Advancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
“There is the further substitution of the amino acid at position 34 which is derivatized at Lysine 26 [34].”
BackgroundEffective and appropriate use of weight loss medication in pediatric obesity: a narrative review
Chung, L. Y. (2024) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2024.00353 · Cited by 8
“Semaglutide is a new GLP-1 RA that is structurally similar to liraglutide, with a longer half-life of 165 hours [35,36].”
BackgroundOral Delivery of Semaglutide and Tirzepatide Using Milk‐Derived Small Extracellular Vesicles
Zhang, Y., Han, J., Wu, W., & Dang, B. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70099 · Cited by 7
“Consistent with our findings, a previously published efficacy study by Novo Nordisk demonstrated that subcutaneous administration of semaglutide (30 nmol/kg) maintained blood glucose reduction for up to 48 h (Lau et al. 2015), but not beyond this time frame (Figure 3C).”
InfluentialSai, W., Tian, H., Yang, K., Tang, D., Bao, J., Ge, Y., Song, X., Zhang, Y., Luo, C., Gao, X., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030578 · Cited by 7
“Similar to GLP-1 related drugs, such as liraglutide and albiglutide, the cleavage site was modified to improve the resistance dipeptidyl peptidase-IV without great change in the peptide squence [29].”
BackgroundKim, T. Y., Nam, Y. R., Park, J., Lee, D., & Kim, H. (2020) · ACS Omega · doi:10.1021/acsomega.0c02555 · Cited by 7
Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor
Zhang, Y., Parrish, K. E., Tortolani, D. R., Poss, M. A., Huang, A., Wan, H., Purandare, A. V., Donnell, A. F., Kempson, J., Hou, X., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02043 · Cited by 8
Miyasaka, K. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.21052 · Cited by 9
Genetically Encoding a Lipidated Amino Acid for Extension of Protein Half‐Life in vivo
Fu, C., Chen, Q., Zheng, F. J., Yang, L., Li, H., Zhao, Q., Wang, X., Wang, L., & Wang, Q. (2018) · Angewandte Chemie · doi:10.1002/ange.201811837 · Cited by 7
Wilbs, J., Raavé, R., Boswinkel, M., Glendorf, T., Rodriguez, D. J., Fernandes, E. F. A., Heskamp, S., Bjørnsdottir, I., & Gustafsson, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02073 · Cited by 7
Lipopeptides as Therapeutics: Applications and In Vivo Quantitative Analysis
Zemenová, J., Sýkora, D., Maletínská, L., & Kuneš, J. (2016) · Bioanalysis · doi:10.4155/bio-2016-0206 · Cited by 7
Specific Activity of Recombinant Modified Human Glucagon-Like Peptide 1
Sannikova, E. P., Bulushova, N. V., Cheperegin, S. E., Zalunin, I. A., Klebanov, F. A., Gracheva, T. S., Yurin, V. L., Rykalina, N. V., Askerova, E. V., Yarotskii, S. V., et al. (2019) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683819070068 · Cited by 8
Tang, C., Li, Q., Deng, X., Wu, W., Liao, L.-F., Liang, K., Huo, R., Li, C., Han, J. D. J., Tang, W., et al. (2020) · RSC Advances · doi:10.1039/d0ra01002b · Cited by 8
Selective Lysine Modification Enabled by Intramolecular Acyl Transfer
Hymel, D., & Liu, F. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c00816 · Cited by 7
Li, W. (2023) · Preprints.org · doi:10.20944/preprints202311.1048.v1 · Cited by 7
Wang, C., Zhang, J., Dong, Y., Xu, J., Lu, J., Ding, C., Cai, Z., & Feng, J. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118266 · Cited by 6
Malgave, A., Akbar, S., Joseph, A., Aishwarya, D., Peraman, R., & Malayandi, R. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114780 · Cited by 7
Pawlas, J., Billing, J. F., Tebikachew, B. E., Wahlström, L., & Haugaard‐Kedström, L. M. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00341 · Cited by 6
Ye, P., Hammer, R. P., Wang, Z., Dhamnaskar, K., Hoarty, M. D., Ma, Z., Tang, G.-Q., DeMarco, S. J., & Ricardo, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02537 · Cited by 6
Zhang, F., Pérez–Tilve, D., Allen, M. R., Metzger, C. E., Dorato, M. A., GEIGER, M. J., & DiMarchi, R. D. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102345 · Cited by 8
“The transition from twice-daily exendin-4 treatment to daily liraglutide administration was followed by weekly dulaglutide and semaglutide, which provide enhanced glycemic control [13,14].”
Biophysical Analysis of Therapeutic Antibodies in the Early Development Pipeline
Willis, L. F., Kapur, N., Radford, S. E., & Brockwell, D. J. (2024) · Biologics · doi:10.2147/btt.s486345 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy
Samanta, A., Bordbar, D. D., Weng, C. Y., & Chancellor, J. R. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000541 · Cited by 7
Molecular dynamics insights into the binding interactions of semaglutide with human serum albumin
Liu, Y., Wen, W., Xu, B., Wang, L., Zhao, Y., & Zhang, J. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2532848 · Cited by 7
“Studies examining the affinity of GLP-1 analogs for albumin have only calculated the relative, not absolute, affinity through analytical ultracentrifugation (Lau et al., 2015) or albumin-conjugated Sepharose resin (Zhang et al., 2021a) (Table S1).”
InfluentialInterface Peptide Mimetics-Rationale and Application as Therapeutic Agents
Srinivasan, M. (2016) · Medicinal Chemistry · doi:10.4172/2161-0444.1000344 · Cited by 7
“Modifications such as attachment of long fatty acids to the peptides or co-synthesis with Fc fragments have been introduced to increase plasma half-life of GLP-1 analogs [28].”
BackgroundGlycaemic control and weight loss with semaglutide in type 2 diabetes
Madsbad, S., & Holst, J. J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30094-3 · Cited by 7
Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists
Icart, L. P., de Souza, F. G., & Lima, L. M. T. R. (2021) · Journal of Microencapsulation · doi:10.1080/02652048.2021.1889059 · Cited by 7
Wang, Y., Xue, F., Cheng, W., Zhao, Q., Song, N., Shi, Z., Liu, H., Li, Y., Tang, Q., Liu, Q., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00067 · Cited by 6
Lipid regulation of the glucagon receptor family
Oqua, A. I., Manchanda, Y., McGlone, E. R., Jones, B. J., Rouse, S. L., & Tomás, A. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0335 · Cited by 8
Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes
Gundapaneni, S. R. C., Burri, R. G., Kaku, R., Mamytova, A., Kondadasula, P., & Tagaev, T. (2025) · Cureus · doi:10.7759/cureus.78555 · Cited by 8
“However, the potential of semaglutide extends beyond weight control, as it exhibits promise for reducing cardiovascular risk along with providing hepatoprotective and neuroprotective benefits [8,36].”
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
“Semaglutide is a human GLP-1 analogue derived from the GLP-1R agonist liraglutide, modified by attaching long chain fatty acids to increase albumin affinity and resistance to DPP4 degradation [43,44].”
BackgroundYousefpour, P., Varanko, A. K., Subrahmanyan, R., & Chilkoti, A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000073 · Cited by 6
Meier, J. J., Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.760153 · Cited by 6
Sawyer, J. R., Audie, J., Swanson, J., Diller, D., Santiago, S., Gribkoff, V. K., Ackerman, A., Hruby, V. J., Gobbo, G., Bellucci, M. A., et al. (2024) · Molecules · doi:10.3390/molecules30010012 · Cited by 5
Advances of deep Neural Networks (DNNs) in the development of peptide drugs
Niu, Y., Qin, P., & Lin, P. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2463319 · Cited by 5
Orlandin, A., Guryanov, I., Giraldo, C., Biondi, B., Santoro, A., Macis, M., Cabri, W., D’Ursi, A. M., Glisenti, A., Formaggio, F., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.4c00515 · Cited by 5
Yu, M., Zhang, C., Xu, H., Dong, Y., Zhu, H., Xia, C., & Feng, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-94014-0 · Cited by 7
“Our results are consistent with recent studies highlighting the importance of side chain modifications in optimizing insulin analogs 18 .”
Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-06245-w · Cited by 8
“These structural changes resulted in a long-acting and highly efficacious drug 18 .”
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.